Interactions sorafenib of and pyrrolidine dithiocarbamate in pancreatic cancer cells
10.3969/j.issn.1007-3969.2013.06.005
- VernacularTitle:索拉菲尼、PDTC联用对胰腺癌细胞株PANC-1的作用研究
- Author:
Guozhong LIU
;
Zheng SHI
;
Huixi GUO
- Publication Type:Journal Article
- Keywords:
Sorafenib;
Pyrrolidinedithiocarbamate;
Cell proliferation;
Cell cycle;
NF-κB
- From:
China Oncology
2013;(6):425-431
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose: Sorafenib, a multiple targeted agent, can inhibit proliferation and induce apoptosis of diverse tumor cell in vitro. It has extensive biological activities, but the pancreatic cancer effect of monotherapy is poor. This may be related to nuclear factor-kappa B (NF-κB) pathway activation in cancer. Therefore, it is necessary to combine with Pyrrolidinedithiocarbamate (PDTC, a NF-κB activation inhibitor) to enhance curative effect. To investigate the influences of cell proliferation, cell cycle and expression of NF-κB via their acting on human pancreatic cancer PANC-1, and explore their possible mechanism. Methods:The experiment groups were divided into sorafenib group with different concentrations (1.5, 3.0, 6.0, 12.0 μmol/L), PDTC group with different concentrations (10.0, 25.0, 50.0, 100.0 μmol/L) and combination group with low concentration (3.0 μmol/L sorafenib+25.0 μmol/L PDTC). The proliferative activity of PANC-1 of each group was measured by MTT assay at different time points of 24
